1. Home
  2. PERI vs TRDA Comparison

PERI vs TRDA Comparison

Compare PERI & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Perion Network Ltd.

PERI

Perion Network Ltd.

HOLD

Current Price

$9.05

Market Cap

412.5M

Sector

Technology

ML Signal

HOLD

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$11.02

Market Cap

404.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PERI
TRDA
Founded
1999
2016
Country
Israel
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
412.5M
404.4M
IPO Year
2006
2021

Fundamental Metrics

Financial Performance
Metric
PERI
TRDA
Price
$9.05
$11.02
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$14.75
$20.00
AVG Volume (30 Days)
261.8K
241.8K
Earning Date
02-18-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$432,361,000.00
$61,520,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$8.59
$3.14
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.00
$4.93
52 Week High
$11.79
$14.27

Technical Indicators

Market Signals
Indicator
PERI
TRDA
Relative Strength Index (RSI) 35.17 55.09
Support Level $9.14 $10.34
Resistance Level $9.40 $12.18
Average True Range (ATR) 0.18 0.75
MACD -0.03 0.03
Stochastic Oscillator 16.88 59.65

Price Performance

Historical Comparison
PERI
TRDA

About PERI Perion Network Ltd.

Perion Network Ltd is a technology company. It offers online advertising and search solutions to brands, agencies, and publishers through desktop, mobile, and social channels. It connects advertisers to consumers across digital advertising channels, including search advertising, social, display, video, digital audio, digital out of home (DOOH), and Connected TV (CTV) advertising. The company earns prime revenue from search advertising and display advertising services. It operates in the business segment of High Impact Advertising solutions. Geographically, the company generates a majority of its revenue from the United States and the rest from other regions.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: